Immunocore
Sid Kaul was appointed to the Immunocore Board of Directors as a Non-Executive Director in June 2022. Sid retired from Novartis as Group Treasurer and Head of Business Planning and Analysis in April 2021 after a 17-year career there. He led Novartis’s Strategic Review and Spin-Off for the Alcon (eye care) business. Sid joined Novartis as CFO of Pharma Europe and subsequently served as CFO of Pharma US following a 20-year career with Procter & Gamble in Financial Planning & Analysis, Strategic Planning, Accounting, and Auditing in the US and Japan.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Immunocore
1 followers
Immunocore is a privately owned British clinical-stage biotechnology company, based in Oxfordshire, which researches and develops biological drugs to treat cancer, infectious diseases and autoimmune diseases using soluble T-cell receptor technology.